Literature DB >> 2830846

Protective effect of recombinant murine interferon beta against mouse hepatitis virus infection.

H Minagawa1, A Takenaka, S Mohri, R Mori.   

Abstract

Recombinant murine interferon beta (rMuIFN-beta) protected susceptible C57BL/6 mice against lethal mouse hepatitis virus (MHV) infection. rMuIFN-beta was life saving if it was given intraperitoneally beginning 21 h before infection and daily thereafter for 9 days, and lengthened the survival time if given from 3 h after infection. rMuIFN-beta treatment beginning 24 h after infection was ineffective. The survival rate was dose-dependent, and the 50% effective dose of rMuIFN-beta for survival was 1780 IU per day. rMuIFN-beta pretreatment inhibited virus growth completely in the brain and moderately in the liver and spleen and prevented severe hepatic lesions. rMuIFN-beta also protected beige mice and cyclophosphamide-treated mice against MHV infection, suggesting that activation of natural killer cells or T-cells by rMuIFN-beta is not critical for protection.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2830846     DOI： 10.1016/0166-3542(87)90079-9

Source DB:  PubMed          Journal:  Antiviral Res        ISSN： 0166-3542            Impact factor:   5.970


  17 in total

1.  Liver-specific alpha 2 interferon gene expression results in protection from induced hepatitis.

Authors:  L Aurisicchio; P Delmastro; V Salucci; O G Paz; P Rovere; G Ciliberto; N La Monica; F Palombo
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

Review 2.  Promoting remyelination through cell transplantation therapies in a model of viral-induced neurodegenerative disease.

Authors:  Vrushali Mangale; Laura L McIntyre; Craig M Walsh; Jeanne F Loring; Thomas E Lane
Journal:  Dev Dyn       Date:  2018-09-06       Impact factor: 3.780

Review 3.  The pathogenesis of murine coronavirus infection of the central nervous system.

Authors:  Thomas E Lane; Martin P Hosking
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

4.  Microglia are required for protection against lethal coronavirus encephalitis in mice.

Authors:  D Lori Wheeler; Alan Sariol; David K Meyerholz; Stanley Perlman
Journal:  J Clin Invest       Date:  2018-01-29       Impact factor: 14.808

5.  Antiviral activity of limitin against encephalomyocarditis virus, herpes simplex virus, and mouse hepatitis virus: diverse requirements by limitin and alpha interferon for interferon regulatory factor 1.

Authors:  Shin-Ichiro Kawamoto; Kenji Oritani; Hideo Asada; Isao Takahashi; Jun Ishikawa; Hitoshi Yoshida; Masahide Yamada; Naoko Ishida; Hidetoshi Ujiie; Hiroaki Masaie; Yoshiaki Tomiyama; Yuji Matsuzawa
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

6.  Inhibition of the alpha/beta interferon response by mouse hepatitis virus at multiple levels.

Authors:  Jessica K Roth-Cross; Luis Martínez-Sobrido; Erin P Scott; Adolfo García-Sastre; Susan R Weiss
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

7.  Mouse hepatitis virus infection of the CNS: a model for defense, disease, and repair.

Authors:  Chris S Schaumburg; Katherine S Held; Thomas E Lane
Journal:  Front Biosci       Date:  2008-05-01

Review 8.  Promoting remyelination: utilizing a viral model of demyelination to assess cell-based therapies.

Authors:  Brett S Marro; Caroline A Blanc; Jeanne F Loring; Michael D Cahalan; Thomas E Lane
Journal:  Expert Rev Neurother       Date:  2014-10       Impact factor: 4.618

9.  CXCR2 signaling and host defense following coronavirus-induced encephalomyelitis.

Authors:  Brett S Marro; Martin P Hosking; Thomas E Lane
Journal:  Future Virol       Date:  2012-04       Impact factor: 1.831

10.  Type I interferon receptor-independent and -dependent host transcriptional responses to mouse hepatitis coronavirus infection in vivo.

Authors:  Matthijs Raaben; Marian J A Groot Koerkamp; Peter J M Rottier; Cornelis A M de Haan
Journal:  BMC Genomics       Date:  2009-08-03       Impact factor: 3.969
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.